This week, Jonathan is joined by Xavier Leleu, world-renowned expert in multiple myeloma, Waldenström's macroglobulinemia, and amyloidosis. The pair discuss groundbreaking advances in clinical trials and the future of myeloma immunotherapy.   Timestamps:  (00:00)-Introduction  (00:59)-Clinical trial breakthroughs in transplant-ineligible myeloma  (03:38)-Minimal residual disease: a key endpoint   (05:21)-Rethinking therapeutic strategies in myeloma   (10:58)-Challenges in late-line myeloma therapies   (13:54)-T-cell-engaging bispecific antibodies   (17:41)-Waldenström's macroglobulinemia and amyloidosis  (21:50)-What's next in multiple myeloma treatment?  (24:43)-Xavier's three wishes for healthcare   

Ver todos los episodios